The Importance of Automation in Genetic Diagnosis: Lessons from Analyzing an Inherited Retinal Degeneration Cohort with the Mendelian Analysis Toolkit (MATK)

Erin Zampaglione, PhD¹, Matthew Maher, MS¹, Emily M. Place, MS¹, Naomi E. Wagner, MS¹, Stephanie DiTroia, PhD³, Katherine R. Chao³, Eleina England, MS³, Broad CMG³, Andrew Catomeris⁴, Sherwin Nassiri⁵, Seraphim Himes⁶, Joey Pagliarulo⁶ Charles Ferguson¹, Eglé Galdikaité-Braziené, PhD¹, Brian Cole, PhD¹, Eric A. Pierce, MD, PhD¹, Kinga M. Bujakowska, PhD¹

<sup>1</sup>Ocular Genomics Institute, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, MA 02114, USA

<sup>2</sup>Invitae Corporation, San Francisco, California, USA.

<sup>3</sup>Center for Mendelian Genomics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA.

<sup>4</sup>Georgetown School of Medicine, Washington, District of Columbia, 20007

<sup>5</sup>Chicago Medical School, Rosalind Franklin University of Medicine & Science, North Chicago, IL, USA.

<sup>6</sup>Touro University California College of Osteopathic Medicine, Vallejo, CA, USA.

<sup>7</sup>MGH Institute of Health Professions, School of Health and Rehab Sciences, Department of Genetic Counseling, Boston, MA, USA.

Corresponding author:

Dr. Kinga Bujakowska

Massachusetts Eye and Ear,

243 Charles Street, Boston, MA 02114

kinga\_bujakowska@meei.harvard.edu, Tel.: (617)-391-5933, Fax: (617)-573-6901

**ABSTRACT**:

**Purpose:** In Mendelian disease diagnosis, variant analysis is a repetitive, error-

prone, and time-consuming process. To address this, we have developed the

Mendelian Analysis Toolkit (MATK), a configurable automated variant ranking program.

**Methods:** MATK aggregates variant information from multiple annotation

sources and uses expert-designed rules with parameterized weights to produce a

ranked list of potentially causal solutions. MATK performance was measured by a

comparison of MATK-aided versus human domain-expert analyses of 1060 inherited

retinal degeneration (IRD) families investigated with an IRD-specific gene panel (589

families) and exome sequencing (471 families).

Results: When comparing MATK-assisted analysis to expert curation, we found

that 97.3% (541/556) of potential solutions found by experts were also identified by the

MATK-assisted analysis. Furthermore, MATK-assisted analysis identified 114 additional

potential solutions. The software also showed utility in data reanalysis after remapping

to the GRCh38 genome build.

Conclusion: MATK expedites the process of identifying likely solving variants in

Mendelian traits and helps to remove variability coming from human error and

researcher bias. MATK facilitates data re-analysis to keep up with the constantly

improving annotation sources and NGS processing pipelines. The software is open

source and available at https://gitlab.partners.org/meei-ogi-

bioinformatics/MendelAnalysis

**Key Words:** Variant ranking, automation, Mendelian analysis,

### **INTRODUCTION:**

Next Generation Sequencing (NGS) has been increasingly used in the study of Mendelian diseases for both new gene discovery and clinical diagnosis<sup>1</sup>. However, as more sequencing data becomes available, the ability to analyze that data must scale appropriately<sup>2</sup>. Automation in read alignment and variant calling is a rapidly advancing field, which has shown consistent progress in speed and accuracy<sup>3,4</sup>. Similarly, the tools and datasets available for variant annotation are constantly improving and expanding<sup>5-7</sup>. as seen in the human genome reference, transcript information, variant population frequency<sup>8,9</sup> and predicted variant effects<sup>10</sup>. However, the interpretation of variants and the determination of a genetic diagnosis remains a primarily manual and iterative task which requires analysts to integrate information from multiple sources. Analysis of single nucleotide variant (SNV) and structural variant (SV) calls generally involves hard filters to reduce the number of plausible causative variants and further cross-referencing with multiple online databases, such as OMIM, ClinVar<sup>11,12</sup> and HGMD<sup>13</sup> (Figure 1A). While quidelines have been developed to standardize both SNV and SV interpretation 14,15 and some work has been done to automate the use of these guidelines<sup>16</sup>, the task remains tedious, error-prone, and highly dependent on the analysts' experience. Furthermore, while the upstream pipelines of variant calling and annotation constantly improve, individual subject data is rarely revisited by the manual curators, even though variant interpretation has been shown to clearly benefit from periodic reanalysis 17-19. The motivation for the development of the Mendelian Analysis Toolkit (MATK) was to increase automation, accuracy, and repeatability of this process.

MATK is a software suite designed to prioritize variants that may be causal for a Mendelian disease. The software is customizable, intended to be tailored to the annotation pipeline and evolving knowledge of genes relevant to the disease under study (Figure 1B). MATK can perform pedigree-aware analysis and incorporate other inputs such as Copy Number Variation (CNV) predictions or arbitrary gene-level annotations such as probability of Loss-of-Function Intolerance (pLI) scores<sup>8</sup> and tissue-specific RNA expression data<sup>20</sup>.

We have validated MATK using a cohort of subjects with inherited retinal degeneration (IRD)<sup>21</sup>. This disease space is an excellent test case for MATK, as IRDs are highly heterogeneous, with over 270 genes known to cause photoreceptor degeneration, following all modes of Mendelian inheritance<sup>22</sup>. Previous work has shown that ~60% of cases can be genetically solved by SNVs and/or CNVs in the exons of known IRD genes<sup>23–27</sup>. We show that MATK performs similarly to human analysts for both panel-based sequencing and exome sequencing (ES), while providing improvements in analysis efficiency, consistency and repeatability.

#### **METHODS**:

## **Ethical guidelines**

The study was approved by the Institutional Review Board at the Massachusetts Eye and Ear (Human Studies Committee MEE, Mass General Brigham, USA) and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all individuals on whom genetic testing and further molecular evaluations were performed.

### Clinical evaluation

Subjects included in the study were recruited and clinically examined at MEE.

Ophthalmic examination included best-corrected Snellen visual acuity, dynamic

Goldmann visual field testing, dark adaptation testing, and full-field electroretinogram

(ERG) testing with assessment of 0.5 Hz ERG amplitude and 30 Hz ERG amplitudes.

## **Sequencing and Annotation**

DNA was extracted from venous blood using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany). All samples underwent Genetic Eye Disease test (GEDi) sequencing as described previously<sup>23</sup>. For inclusion in the cohort, samples were required to have >20x depth of coverage for >90% of the reads. VCF files were generated using the Genome Analysis Toolkit (GATK) version 3 (https://software.broadinstitute.org/gatk/), and annotated using VEP<sup>5</sup> and VCFAnno<sup>28</sup>. VEP provided transcript-specific sequence-consequence annotations from GENCODE v19 and regulatory annotations from ENCODE<sup>29</sup>. VCFAnno was used to annotate the variants with gnomAD<sup>8,30</sup>, ClinVar<sup>11,12</sup>, HGMD<sup>13</sup>, and CADD<sup>10</sup>. CNV predictions were produced using gCNV<sup>4</sup>, and the known *MAK*-Alu structural variant was identified using a custom script<sup>31</sup>.

Exome sequencing was performed at the Center for Mendelian Genomics at the Broad Institute of MIT and Harvard using methodology described previously<sup>8</sup>. Briefly, whole exome sequencing and data processing were performed by the Genomics Platform at the Broad Institute of MIT and Harvard with an Illumina Nextera or Twist exome capture (~38 Mb target) and sequenced (150 bp paired reads) to cover >80% of targets at 20x and a mean target coverage of >100x. Exome sequencing data was processed through a pipeline based on Picard and mapping done using the BWA aligner to the human genome build 38. Variants were called using Genome Analysis Toolkit (GATK) HaplotypeCaller package version 3.5. The data were displayed and analyzed with an online tool (https://segr.broadinstitute.org).

## **MATK** configuration

Variant-level information used in this study consisted of an annotated variant call format (VCF) file and CNV predictions from gCNV. For the GEDi panel sequence analyses, MATK's Annotation Binding Code (ABC) was configured based on prior expert knowledge as a summation of 6 unique functions pertaining to 1) sequence consequence, 2) population frequency, 3) ClinVar pathogenicity classification, 4) HGMD pathogenicity classification, 5) CADD score, and 6) regulatory status, with the final score capped at 20 (Figure 2A, Supplementary Table 1A). For GEDi analyses, the gene-level information, contained in the Gene Model File (GMF), was configured with a default maximum likely frequency for autosomal recessive (AR) and X linked (XL) genes at 0.002, and for autosomal dominant (AD) genes at 0.00001, although exceptions were made for some genes based on known allele frequencies for IRD variants (Figure 2B, Supplementary Table 2). Once MATK had ranked variants for each inheritance pattern,

an analyst independently reviewed the ranked variants for each sample and determined which ranked variants were plausible solutions.

For analysis of the ES cohort, a generalized version of MATK was used, without input of prior expert knowledge. The ABC was configured as a summation of 6 unique functions pertaining to 1) sequence consequence, 2) population frequency, 3) CADD score, 4) regulatory status 5) transcript expression level in retina, and 6) variant quality score (Supplementary Table 1B). The GMF was left empty aside from the default maximum likely frequencies of AR and XL at 0.001, and AD at 0.00001.

## **Exomiser Configuration**

Another variant ranking software, Exomiser, was run using the code available at <a href="https://exomiser.github.io/Exomiser/manual/7/example/test-analysis-genome/">https://exomiser.github.io/Exomiser/manual/7/example/test-analysis-genome/</a>. The PhenIX prioritizer and OMIM prioritizer were used. HPO terms used in the analysis were: ("HP:0000510", "HP:0000548", "HP:0007754", "HP:0000546", "HP:0000608", "HP:0007737", "HP:0007722", "HP:0008527", "HP:0008615", "HP:0030610", "HP:0030611"). Using the genePanelFilter option, we utilized the same gene list from the MATK GMF (Supplementary Table 2). The resulting scores were ordered first by EXOMISER\_GENE\_COMBINED\_SCORE, then by EXOMISER\_VARIANT\_SCORE to create a ranking of variant scores.

#### **RESULTS:**

## MATK functionality

The MATK software was developed to increase automation and accuracy of variant interpretation in the context of Mendelian disease. MATK is a suite of Python scripts that outputs a ranked list of variants and/or variant pairs according to a customizable set of rules and parameterized weighting functions, using sample-specific and gene-specific inputs. Sample-specific files include the annotated VCF, as well as optional inputs such as a structural variation file and pedigree information. Gene-specific files are meant to be customized for a given disease space and may include a curated list of known disease-associated genes with their expected causal variant frequencies and inheritance mode, or other gene-level information relevant to the studied disease (e.g. gene expression, pLI scores). Variant-level information is used in the Annotation Binding Code (ABC), a customizable component of the software that scores each variant for functional consequence, population frequency, ClinVar and/or HGMD pathogenicity classification, or in silico predictions of deleteriousness. The ABC assigns scores differently to the genes with known or presumed autosomal recessive (AR), Xlinked (XL) or autosomal dominant (AD) inheritance (Figure 2A). For example, loss-offunction variants are scored higher in AR, XL genes and AD haploinsufficient genes than in genes with AD inheritance known for a gain of function or dominant negative mechanism of disease. The gene-level information is encoded in the Gene Model File (GMF), which contains a default maximum likely frequency of a variant for each inheritance mode for a given disease or gene (Figure 2B, Supplementary Table 2). Once the GMF and ABC have executed, MATK calculates a score for each variant in a

sample based on the specified inheritance mode. MATK then ranks the variants by score, and for the AR inheritance mode, creates ranked pairs of variants within each gene. The final step requires an analyst to determine if any of the ranked variants are accepted as candidate solutions.

MATK-assisted analysis of panel sequencing data improves genetic diagnosis To test the practicality of MATK, we performed a comparative analysis of a probandonly IRD subject cohort. We analyzed 589 primarily early-onset IRD samples in two independent rounds. The first round of analysis utilized our conventional analysis protocol, starting with an application of hard filters to the dataset, which can often reduce the number of variants from hundreds or thousands down to tens. The remaining variants, which are unranked, are then evaluated based on frequency, variant type, computer prediction models, and prior reports to identify variants of interest. CNVs are checked separately, often second, with special attention to "one hit" cases or cases with no SNVs of interest. The second round of analysis incorporated the MATK software to prioritize the variants for analysts to review. In both rounds, the analysts would choose one of two outcomes: the case was either potentially solved by a single or set of potentially pathogenic variants, or the case was left unsolved. Finally, all variants that were identified as potentially solving were classified using the ACMG/AMP guidelines, and based on these classifications, solutions were split into 3 confidence tiers: Tier 1 solutions comprised of likely pathogenic (LP) or pathogenic (P) variants; tier 2 solutions comprised of AR genes with one LP/P variant and one variant of uncertain significance (VUS); and tier 3 solutions comprised of two VUSs in an AR gene or one VUS in an AD

gene. Samples in which a chosen variant was classified as benign (B) or likely benign (LB) were considered as unsolved. Of the 589 cases, 502 (85.2%) had identical outcomes using both protocols, consisting of 245 tier 1 solutions, 55 tier 2 solutions, 23 tier 3 solutions, and 179 unsolved (Figure 3, Supplementary Table 3). Overall, there were more solutions of each tier with the MATK-assisted analysis than in the conventional analysis ( $\chi^2$  test, df=3, p=0.0005) (Figure 3A) and the MATK-assisted analysis identified 97.3% (323/332) of the potential solutions found by the conventional analysis. Of the 86 samples in which there was a discrepancy, 51 involved high confidence, tier 1 solutions. Forty-nine had a tier 1 solution discovered through the MATK assisted analysis and 3 via the conventional analysis (Figure 3B). Of the 49 tier 1 solutions found exclusively by MATK, 24 solutions involved structural variants, 16 solutions were missed in the conventional analysis due to human error and 8 were missed because of upstream pipeline errors related to issues with the variant caller, gene transcripts, and hard filters that resulted in the likely solving variants being hidden from the analysts. The last tier 1 solution missed in conventional analysis and found using MATK was a sample (OGI2423\_003982) in which the two analysis protocols resulted in two different potential genetic solutions (Supplementary Table 3). In this case, the ACMG/AMP classification clarified that the MATK-assisted analysis chose the most likely solution. Of the three tier 1 solutions found exclusively using the conventional analysis, one solution was a mitochondrial solution (OGI2050 003476, MT-ATP6 m.8993T>G), which the MATK program did not consider in any of its inheritance modes. One solution was missed because the gene transcript model incorrectly labeled a variant as non-coding, which caused the variant to be scored so

low as to not appear in the MATK output (OGI2401\_003960, *NR2E3*: c.932G>A, p.(Arg311Gln); c.151G>A, p.(Gly51Arg)), and one solution was presented by MATK but was missed due to human error (OGI1257\_002429, *USH2A* c.11864G>A, p.(Trp3955Ter); c.13342\_13347del, p.(Asp4448\_Ser4449del)) (Supplementary Table 3).

The remaining discrepant solutions (35 cases, 29 from the MATK assisted analysis and 6 from the conventional analysis) involved low confidence solutions (tier 2 and 3), which were interpreted differently in the two different analysis rounds. Reviewing these samples using the ACMG/AMP classification guidelines found that these potentially solving solutions had one or more VUS variants, and thus the genetic cause could not be resolved unequivocally. Therefore, for the purpose of the comparison between the conventional and MATK-assisted analysis, the 297 high-confidence solutions are most informative, where 294 (99.0%) were obtained with the MATK-assisted analysis, and 248 (83.5%) were obtained with the conventional analysis.

### MATK facilitates data reanalysis after upstream pipeline changes

Routine reanalysis of all the sequenced samples with a conventional protocol each time a reference genome, transcript model, other crucial database or software is updated is time consuming for a genetic diagnostic lab, however an automated process enables regular reanalysis. We have therefore used the MATK-assisted analysis to understand how updating the human reference genome and associated datasets can affect diagnostic rate in the known IRD genes. The sequence reads for all of 589 samples were realigned to hg38. Reanalysis with MATK and comparison with the existing

solutions produced 13 additional potential solutions, four of which were ultimately placed in the tier 1 category. Of these four, one was found because of a new ClinVar entry that brought the variant to the attention of the analyst (OGI2484\_004049, *CERKL*: hom c.237\_238+13del), one was found because of an updated transcript model (OGI2114\_003548, *NR2E3*: hom c.932G>A, p.(Arg311Gln)), and two were found because of updated gCNV results (OGI2201\_003682, *PRPF31*: hg38:chr19:54115160-54118353:copy number 3), and (OGI1943\_003348, *IFT172*: hg38: chr2:27458072-27465609:copy number 1) (Supplementary Table 4).

### MATK improves accuracy of paired SNV and CNV calls

In three cases, where a heterozygous deletion paired with an overlapping pathogenic SNV, the variant was called as homozygous. In the conventional analysis, the erroneous homozygous call was sufficient for the analysts to conclude that the homozygous pathogenic variant was a solution. The MATK-assisted analysis gave a more accurate genetic solution in each case. For sample OGI1820\_003160, a nonsense variant in *MERTK* (hg19:chr2:112732995G>T, c.1090G>T, p.(Glu364Ter)) overlapped with a deletion of hg19:chr2:112655935-112787192. For OGI1973\_003378, a known IRD pathogenic variant in *USH2A* (hg19:chr1: 216420460C>A, c.2276G>T, p.(Cys759Phe)) overlapped with a deletion of hg19:chr1:216380365-216424690. Lastly, for OGI2285\_003796, a missense variant in *NMNAT1* (hg19:chr1: 10042553G>A, c.634G>A, p.(Val212Met)) overlapped with a deletion of hg19:chr1:10003159-10044256. (Supplemental Table 3).

## **MATK** comparison to Exomiser

We next compared MATK to Exomiser, an open source variant prioritization software<sup>32</sup>. For a subset of our panel sequenced cohort (96 samples), we ran Exomiser in PhenIX mode, which prioritizes only variants in known human disease genes. We then compared the top Exomiser rankings to the previously established likely solutions found by analysts using MATK. Data was reviewed to determine if Exomiser ranked the same solution, a "partial" solution (for example, ranking only one variant in an AR solution), or did not rank any of the established solution. In these samples, there were 34 tier 1 solutions as established by the previous analysis. We found that Exomiser presented a full solution only for 17 cases (two variants in an AR and one variant in an AD or XL case) and in 11 cases only one variant from an AR solution was presented. Of the full solutions, 12 were presented in the top 3 suggestions and five in the top 25. A similar trend was observed in the tier 2 and 3 solutions presented by Exomiser. No additional solutions in the 39 unsolved IRD patients were revealed by the Exomiser analysis (Figure 4, Supplementary Table 5).

### MATK results in exome sequencing

To test the utility of MATK in the analysis of exome data (ES), we ran MATK on 471 exome sequenced cases, consisting of both proband-only cases and families. After examining the sequencing results with both the conventional analysis and MATK assisted analysis, we found the two protocols agreed in 429 (91.1%) of cases, consisting of 142 tier 1 samples, 39 tier 2 samples, 37 tier 3 samples, and 211 unsolved (Figure 5A, B, Supplemental Table 6). The MATK-assisted analysis was able to find 97.3%, (218/224) of the solutions found by conventional analysis. Of the tier 1 solutions,

there were 4 cases in which the conventional analysis found solutions that MATK missed. These consisted of one family with a partial penetrance inheritance pattern (OGI842, *PRPF31* c.73\_166dup, p.(Asp56GlyfsTer33)), and three solutions that were found in a genomic region where difficulties in sequencing resulted in heterozygous calls on the X chromosome, even though the samples in question were male, and thus failed the inheritance checks in MATK (OGI1426, *RPGR* c.1582\_1585del, p.(Thr528LeufsTer4)), (OGI1741, *RPGR* c.2909del, p.(Gly970GlufsTer119)), (OGI1735, *RPGR* c.2506dup, p.(Glu836GlyfsTer243)). The MATK-assisted analysis found 26 possible new solutions missed by conventional analysis. Specifically, 20 of the 26 involved CNVs and 6 of the 26 were missed because of shortcomings in the analysis pipeline such as filtering out common pathogenic variants and gene transcript errors (Figure 5B, Supplementary Table 6).

Next, we tested a more generalized version of MATK which excluded the use of known IRD genes or prior variant reports. The purpose of this test was to produce a "mock scenario" in which MATK might be run on a disease cohort in an early gene discovery phase, when less is known about genetic causality of that disease. For this trial, we took a subset of the ES cohort consisting of 55 families of trios or larger. As with Exomiser, we considered whether the generalized MATK ranked the established solutions fully, partially, or not at all. In order to narrow down the gene search without utilizing known disease genes or reported variants, we used publicly available gene expression data in the relevant tissue (in this case, retina)<sup>33</sup> and used a weighting function that strongly discounted genes expressed at low levels in retina (+5 points if In(transcripts per million) > 2.0). Of the 21 tier 1 solutions uncovered with the IRD-specific MATK, the generalized

MATK recapitulated 17 fully, 3 partially, and missed one solution entirely. For tier 2 and tier 3 solutions, the generalized MATK performed similarly to the IRD-specific MATK, missing only one solution partially in each category (Figure 5C, Supplementary Table 6). Of interest is a case in which the generalized MATK suggested a solution that the IRD-specific MATK missed, although it was found in the conventional analysis as a tier 1 solution. In family OGI842, a variant in *PRPF31* (c.73\_166dup, p.(Asp56GlyfsTer33)) exhibited partial penetrance, with the haploinsufficient dominant variant appearing once in a reportedly unaffected family member. Because MATK was not coded to accommodate for partial penetrance cases, the variant failed the inheritance check. However, as the generalized MATK did not use the customized GMF, it did not treat *PRFP31* as a haploinsufficient dominant gene, and thus ranked the variant as a single hit recessive.

#### **DISCUSSION**

We have demonstrated the utility of an automated variant analysis process in providing genetic diagnoses using a cohort of patients with retinal disorders. Our MATK software was practical and efficient for finding causal variants in the known IRD genes in targeted gene panel data and in ES data. The MATK-assisted analysis showed a higher number of plausible solutions than the non-MATK-assisted analysis, largely due to the customization options in MATK, which allow for incorporation of the existing scientific knowledge about the genetics of a disorder into the ranking algorithms. Even with minimal customization, many clear genetic solutions were still ranked highly by MATK in ES data. In addition, we showed the utility of MATK for rapid re-analysis of a large cohort after realignment to a new genome build and transcript model, which resulted in finding new solutions.

Comparison between the conventional and MATK-assisted analysis showed a high level of reproducibility, with the MATK-assisted analysis identifying 97.3% of potential solutions that were found using a more conventional analysis in both IRD gene panel sequencing (323/332) and exome sequencing (218/224). Furthermore, the MATK-assisted analysis identified 78 additional potential solutions for the gene panel cohort, and 36 additional potential solutions in the exome cohort, the majority of which consisted of high confidence, tier 1 solutions (49/78 for the gene panel cohort and 26/36 for the exome cohort). Some of these new findings were easily anticipated, such as the solutions found with MATK's improved utilization of the structural variation data. Some of the high confidence solutions were missed by human error, which primarily involved samples with many rare variants passing the hard filtering thresholds, creating more

visual noise in the variant viewer software used in the conventional analysis. However, some of the discrepancies exposed deeper shortcomings in our analysis pipelines, for example, certain issues in the variant annotation and filtering steps resulted in the solution not being available to the analysts. Since these upstream sequence data processing and annotation pipeline are often being updated and improved, we anticipate that regular data re-analysis will uncover such missing diagnoses. In the gene panel cohort, the MATK assisted analysis missed three high confidence solutions. Only one of these, the mitochondrial DNA solution, represented a true shortcoming in the software, while the other missed solutions were due to human error or erroneous variant annotation leading to inadequate variant scoring by the software. With the exome sequencing cohort, four high confidence solutions were missed in the MATK assisted analysis, all of which were due to atypical inheritance situations.

There were 35 discordant results in the gene panel cohort and 12 discordant results in the exome cohort where the potential solution involved at least one VUS (tier 2 and 3 solutions). We believe these discrepancies stem from the uncertainty of the variant's potential disease-involvement. In these cases, regardless of which variant analysis protocol is used, an analyst might consider a VUS differently depending on if they are in a clinical mindset, i.e. looking for unambiguous solutions, or a research mindset, i.e. looking at candidate variants that may need more evidence before they can be designated as solving<sup>19</sup>. Differences in interpreting candidate variants, even when using standardized guidelines, are common and have been reported previously<sup>34</sup>. Even though they are ambiguous, a potential recessive solution with one P/LP variant and one VUS can be worth further investigation, as shown in previous studies that

determined a single pathogenic variant paired with a clear phenotypic association strongly implies the solution will be found in that gene<sup>35</sup>. Sequence data for a great number of subjects (113/589 for the gene panel cohort and 88/471 for the exome cohort) contain such ambiguous solutions. This further highlights the utility of using a software with a reproducible output to assist with variant analysis, as such VUS containing solutions should be periodically reinvestigated as more evidence is accumulated to push the variant toward either a pathogenic or benign interpretation. Using MATK allowed us to identify three false homozygous SNV calls when a variant was most likely in trans with a heterozygous CNV deletion. Critically, the samples with false homozygous pathogenic calls would not have been further investigated in our conventional analysis protocol. This would lead to providing an inaccurate genetic diagnosis, incorrect genetic counseling to family members regarding their carrier status, and misreporting of the allele frequency of that variant. In the era of emerging CRISPRbased genetic therapies, where variant or exon-specific therapies will one day be more common, such inaccurate diagnosis could also lead to an erroneous gene therapy recommendation<sup>36</sup>. For example, the ongoing clinical trial NCT03872479 involves a gene editing product specific for the intronic variant (CEP290: c.2991+1655A>G), and whether the patient is compound heterozygous versus homozygous could potentially

For a subset of our patients, we have benchmarked MATK against another freely available variant prioritization software, Exomiser, using a setting designed for known human disease genes (PhenIX). For a well-described monogenic disease space such as IRDs, MATK outperforms Exomiser in finding likely pathogenic variants. Other

impact the efficacy of the treatment.

software such as Variant Score Ranker<sup>37</sup>, Variant Ranker<sup>38</sup>, Diploid Moon<sup>39</sup>, and EmedGene<sup>40</sup>, have been developed in recent years to address the issue of variant prioritization and new gene discovery, and programs such as PathoMAN are designed to classify variants according to ACMG/AMP guidelines<sup>16</sup>. There has been great success in using these programs to help find disease causing variants<sup>41,42</sup>. Our MATK software differs from these in that it is far more customizable and can incorporate disease-specific information.

For IRDs, there are over 270 known disease genes<sup>22</sup>, and knowledge about the plausible pathogenic variant frequency and inheritance modes have been incorporated into the MATK via one of the input files, the Gene Model File. However, not all Mendelian disorders have been so well characterized and many new disease genes remain to be discovered. Thus, we have tested a more general configuration of MATK on an exome sequencing dataset. We emulated a search for new disease genes by removing the disease-specific genetic information and the use of prior genetic knowledge such as ClinVar scores, and by including retinal RNA expression data to identify genes that are relevant to eye tissue. For many disease spaces, other genelevel data sets could be included such as loss-of-function or missense intolerance (pLI) scores<sup>8</sup>, however these are not useful for IRDs because vision loss does not influence reproductive fitness and thus known pathogenic variants are not depleted in the general population as in other systemic diseases. Our results showed that MATK was able to prioritize most of the solutions and thus could be used as a first pass analysis for other Mendelian diseases with minimal customization. As more knowledge is acquired about a specific disease, MATK customization can be added in an iterative process, allowing

all previously hard-won knowledge gains to accumulate to the benefit of future analysts. Even for such well characterized disorders as IRD, only about 60% of IRD patients receive genetic diagnoses in the known genes<sup>23–27</sup>, meaning there still may be undiscovered pathogenic genes. In future studies, especially as the field moves to sequence exomes and genomes of unsolved families, we would consider incorporating other dataset such as SpliceAl<sup>43</sup>, GO terms<sup>44</sup>, String terms<sup>45</sup>, HPO terms<sup>46</sup>, and Monarch data<sup>47</sup> into MATK.

In summary, we have shown the utility and benefits of automated variant analysis in Mendelian disease. We demonstrated this through our open-source variant ranking software, MATK, which was designed to incorporate the available knowledge of a particular field. This highly customizable software increases consistency and reproducibility, making bulk re-analysis of a cohort a feasible option as upstream components of the variant annotation pipeline continually improve. Integrating automated variant ranking tools into analysis protocols is a critical step in improving Mendelian disease diagnosis and new gene discovery in both clinical and research settings.

## **Data availability**

Variants will be available through ClinVar (Submission Number SUB9430499, SUB9443633, and SUB9363246) and in Supplemental Materials. Sequence data will be available through dbGaP and upon request.

## Acknowledgments

This work was supported by grants from SPARK Therapeutics Inc. (EAP), the National Eye Institute [R01EY012910 (EAP), R01EY026904 (KMB/EAP) and P30EY014104 (MEEI core support)], and the Foundation Fighting Blindness [EGI-GE-1218-0753-UCSD, (KMB/EAP)]. Exome sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grant UM1HG008900 and in part by National Human Genome Research Institute grant R01 HG009141. The authors thank all subjects for their participation in this study and the OGI Genomics Core members for their experimental assistance.

### **Author Information**

Conceptualization: E.Z., M.M., E.M.P, K.M.B; Data curation E.Z., E.M.P., N.E.W., S.D., K.R.C., E.E, B.CMG, A.C., S.N., S.H., J.P., K.M.B.; Formal Analysis: E.Z., K.M.B; Funding acquisition: E.M.P., B.CMG, E.A.P., K.M.B.; Investigation: E.Z., M.M., B.CMG, E.G.B., K.M.B.; Software: M.M, C.F., B.C.; Visualization: E.Z., K.M.B.; Writing – original

draft: E.Z, K.M.B; Writing – review & editing: E.Z, M.M., E.M.P., N.E.W., S.D., K.R.C., B.C., K.M.B., E.M.P.

## **Ethics Declaration**

The study was approved by the Institutional Review Board at the Massachusetts Eye and Ear (Human Studies Committee MEE, Mass General Brigham, USA) and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all individuals on whom genetic testing and further molecular evaluations were performed.

#### **REFERENCES**

- 1. Jamuar SS, Tan E-C. Clinical application of next-generation sequencing for Mendelian diseases. *Hum Genomics*. 2015;9(1):10. doi:10.1186/s40246-015-0031-5
- 2. Pandey KR, Maden N, Poudel B, Pradhananga S, Sharma AK. The curation of genetic variants: difficulties and possible solutions. *Genomics Proteomics Bioinformatics*. 2012;10(6):317-325. doi:10.1016/j.gpb.2012.06.006
- 3. Laurie S, Fernandez-Callejo M, Marco-Sola S, et al. From Wet-Lab to Variations: Concordance and Speed of Bioinformatics Pipelines for Whole Genome and Whole Exome Sequencing. *Hum Mutat*. 2016;37(12):1263-1271. doi:10.1002/humu.23114
- 4. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*. 2010;20(9):1297-1303. doi:10.1101/gr.107524.110
- 5. The Ensembl Variant Effect Predictor | Genome Biology | Full Text. Accessed May 18, 2020. https://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-0974-4
- 6. McCarthy DJ, Humburg P, Kanapin A, et al. Choice of transcripts and software has a large effect on variant annotation. *Genome Med.* 2014;6(3):26. doi:10.1186/gm543
- 7. Wertz J, Liao Q, Bair TB, Chimenti MS. PyVar: An Extensible Framework for Variant Annotator Comparison. *bioRxiv*. Published online September 30, 2016:078386. doi:10.1101/078386
- 8. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016;536(7616):285-291. doi:10.1038/nature19057
- 9. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
- 10. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet*. 2014;46(3):310-315. doi:10.1038/ng.2892
- 11. Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of clinically relevant variants. *Nucleic Acids Res.* 2016;44(D1):D862-D868. doi:10.1093/nar/gkv1222
- 12. Landrum MJ, Lee JM, Benson M, et al. ClinVar: improving access to variant interpretations and supporting evidence. *Nucleic Acids Res*. 2018;46(Database issue):D1062-D1067. doi:10.1093/nar/gkx1153

- 13. Stenson PD, Mort M, Ball EV, Shaw K, Phillips AD, Cooper DN. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. *Hum Genet*. 2014;133(1):1-9. doi:10.1007/s00439-013-1358-4
- 14. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-423. doi:10.1038/gim.2015.30
- 15. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). *Genet Med.* Published online November 6, 2019:1-13. doi:10.1038/s41436-019-0686-8
- 16. Ravichandran V, Shameer Z, Kemel Y, et al. Toward automation of germline variant curation in clinical cancer genetics. *Genet Med*. Published online February 21, 2019. doi:10.1038/s41436-019-0463-8
- 17. Need AC, Shashi V, Schoch K, Petrovski S, Goldstein DB. The importance of dynamic reanalysis in diagnostic whole exome sequencing. *J Med Genet*. 2017;54(3):155-156. doi:10.1136/jmedgenet-2016-104306
- 18. Wenger AM, Guturu H, Bernstein JA, Bejerano G. Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers. *Genet Med*. 2017;19(2):209-214. doi:10.1038/gim.2016.88
- 19. Eldomery MK, Coban-Akdemir Z, Harel T, et al. Lessons learned from additional research analyses of unsolved clinical exome cases. *Genome Med*. 2017;9(1). doi:10.1186/s13073-017-0412-6
- 20. Lonsdale J, Thomas J, Salvatore M, et al. The Genotype-Tissue Expression (GTEx) project. *Nat Genet*. 2013;45(6):580-585. doi:10.1038/ng.2653
- 21. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. *Prog Retin Eye Res.* 2010;29(5):335-375. doi:10.1016/j.preteyeres.2010.03.004
- 22. RetNet Retinal Information Network. Accessed April 9, 2020. https://sph.uth.edu/retnet/home.htm
- 23. Consugar MB, Navarro-Gomez D, Place EM, et al. Panel-based genetic diagnostic testing for inherited eye diseases is highly accurate and reproducible, and more sensitive for variant detection, than exome sequencing. *Genet Med.* 2015;17(4):253-261. doi:10.1038/gim.2014.172

- 24. Zampaglione E, Kinde B, Place EM, et al. Copy-number variation contributes 9% of pathogenicity in the inherited retinal degenerations. *Genet Med*. Published online February 10, 2020:1-9. doi:10.1038/s41436-020-0759-8
- 25. Weisschuh N, Mayer AK, Strom TM, et al. Mutation Detection in Patients with Retinal Dystrophies Using Targeted Next Generation Sequencing. *PLOS ONE*. 2016;11(1):e0145951. doi:10.1371/journal.pone.0145951
- 26. Zhao L, Wang F, Wang H, et al. Next-generation sequencing-based molecular diagnosis of 82 retinitis pigmentosa probands from Northern Ireland. *Hum Genet*. 2015;134(2):217-230. doi:10.1007/s00439-014-1512-7
- 27. Boulanger-Scemama E, El Shamieh S, Démontant V, et al. Next-generation sequencing applied to a large French cone and cone-rod dystrophy cohort: mutation spectrum and new genotype-phenotype correlation. *Orphanet J Rare Dis.* 2015;10. doi:10.1186/s13023-015-0300-3
- 28. Pedersen BS, Layer RM, Quinlan AR. Vcfanno: fast, flexible annotation of genetic variants. *Genome Biol.* 2016;17(1):118. doi:10.1186/s13059-016-0973-5
- 29. Dunham I, Kundaje A, Aldred SF, et al. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012;489(7414):57-74. doi:10.1038/nature11247
- 30. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *bioRxiv*. Published online April 8, 2020:531210. doi:10.1101/531210
- 31. Bujakowska KM, White J, Place E, Consugar M, Comander J. Efficient In Silico Identification of a Common Insertion in the MAK Gene which Causes Retinitis Pigmentosa. *PLOS ONE*. 2015;10(11):e0142614. doi:10.1371/journal.pone.0142614
- 32. Smedley D, Jacobsen JOB, Jäger M, et al. Next-generation diagnostics and disease-gene discovery with the Exomiser. *Nat Protoc.* 2015;10(12):2004-2015. doi:10.1038/nprot.2015.124
- 33. Ratnapriya R, Sosina OA, Starostik MR, et al. Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration. *Nat Genet*. Published online February 11, 2019:1. doi:10.1038/s41588-019-0351-9
- 34. Harrison SM, Dolinsky JS, Knight Johnson AE, et al. Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVar. *Genet Med*. 2017;19(10):1096-1104. doi:10.1038/gim.2017.14
- 35. Kimberling WJ. Estimation of the frequency of occult mutations for an autosomal recessive disease in the presence of genetic heterogeneity: application to genetic hearing loss disorders. *Hum Mutat*. 2005;26(5):462-470. doi:10.1002/humu.20221

- 36. DiCarlo JE, Mahajan VB, Tsang SH. Gene therapy and genome surgery in the retina. *J Clin Invest.* 2018;128(6):2177-2188. doi:10.1172/JC|120429
- 37. Du J, Sudarsanam M, Pérez-Palma E, et al. Variant Score Ranker—a web application for intuitive missense variant prioritization. Hancock J, ed. *Bioinformatics*. Published online April 25, 2019. doi:10.1093/bioinformatics/btz252
- 38. Alexander J, Mantzaris D, Georgitsi M, Drineas P, Paschou P. Variant Ranker: a web-tool to rank genomic data according to functional significance. *BMC Bioinformatics*. 2017;18(1):341. doi:10.1186/s12859-017-1752-3
- 39. Diploid Diagnosing Rare Diseases. Accessed January 11, 2021. http://www.diploid.com/moon
- 40. Machine Learning Genomic Analysis Platform. Accessed January 11, 2021. https://www.emedgene.com/
- 41. Ji J, Shen L, Bootwalla M, et al. A semiautomated whole-exome sequencing workflow leads to increased diagnostic yield and identification of novel candidate variants. *Mol Case Stud*. 2019;5(2):a003756. doi:10.1101/mcs.a003756
- 42. Basel-Salmon L, Orenstein N, Markus-Bustani K, et al. Improved diagnostics by exome sequencing following raw data reevaluation by clinical geneticists involved in the medical care of the individuals tested. *Genet Med Off J Am Coll Med Genet*. 2019;21(6):1443-1451. doi:10.1038/s41436-018-0343-7
- 43. Jaganathan K, Panagiotopoulou SK, McRae JF, et al. Predicting Splicing from Primary Sequence with Deep Learning. *Cell.* 2019;176(3):535-548.e24. doi:10.1016/j.cell.2018.12.015
- 44. Ashburner M, Ball CA, Blake JA, et al. Gene Ontology: tool for the unification of biology. *Nat Genet*. 2000;25(1):25-29. doi:10.1038/75556
- 45. von Mering C, Jensen LJ, Snel B, et al. STRING: known and predicted protein—protein associations, integrated and transferred across organisms. *Nucleic Acids Res*. 2005;33(Database Issue):D433-D437. doi:10.1093/nar/gki005
- 46. Köhler S, Carmody L, Vasilevsky N, et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. *Nucleic Acids Res*. 2019;47(Database issue):D1018-D1027. doi:10.1093/nar/gky1105
- 47. Mungall CJ, McMurry JA, Köhler S, et al. The Monarch Initiative: an integrative data and analytic platform connecting phenotypes to genotypes across species. *Nucleic Acids Res.* 2017;45(D1):D712-D722. doi:10.1093/nar/gkw1128

#### FIGURE LEGENDS:

Figure 1: Standard variant assessment protocol for human analysts. A) The process of NGS variant analysis without MATK, which involves hard filtering of variants down to a manageable list, then using the analyst's disease-specific expertise to weigh the evidence for each variant, often going through multiple iterations of filtering. B) In the analysis with MATK, much of the domain expertise is encoded in the Gene Model File (GMF) and the evidence is weighed by the Annotation Binding Code (ABC) which allows for a standardized analysis. The GMF and the ABC are fully customizable. Created with BioRender.com


Figure 2: The two major components of MATK. A) The Annotation Binding Code (ABC), is the weighting function used to assign a score to each variant. The function used on the IRD cohort was tuned empirically, and utilized population frequency, sequence consequence, CADD scores, regulatory information, and prior reports, capped at 20 points. B) The Gene Model File (GMF) encapsulates disease specific gene-level information such as known inheritance modes, allele frequencies, haploinsufficient dominant status, and level of confidence in the field that a gene may be disease causing.


Figure 3: Comparison of 589 panel sequenced IRD patients analyzed with and without MATK assistance. A) Using MATK resulted in analysts selecting more potential solutions at each confidence tier. B) There was a high degree of overlap

between the two methods, with MATK assisted analysts missing only 9 potential solutions (3 in Tier 1) and non-MATK assisted analysts missing 78 potential solutions (49 in Tier 1).

Figure 4: Comparison of Exomiser and MATK in 96 panel sequenced samples. Out of 56 total solutions found using MATK, Exomiser successfully ranked 20 total solutions, 15 in tier 1, three in tier 2, and two in tier 3, without finding any new solutions that were missed by MATK.


Figure 5: Comparison of 471 exome sequenced IRD patients analyzed with MATK versus the conventional analysis pipeline. A) MATK-assisted analysis resulted in analysts selecting more solutions at confidence tiers 1 and 2, and the same number of potential solutions at tier 3. B) There was a high degree of overlap with the two methods, with most of the discrepancies coming from CNVs that were missed in the conventional pipeline. C) Comparison of gene-specific MATK vs generalized MATK. Out of 27 total solutions, the generalized MATK successfully ranked 17 of 21 solutions in tier 1, with additional 3 partial solutions (one hit of a recessive solution). All tier 2 and 2/3 of tier 3 solutions were also fully identified. The generalized MATK was able to find one solution that was unsolved in the gene-specific MATK analysis run, but was determined to be a tier 1 solution.





Α

**Annotation Binding Code Example** 



В

## Gene Model File Example

